Inventor · disambiguated record
Patricia Rao
Also filed as: RAO PATRICIA · RAO PATRICIA E · RAO PATRICIA ELAINE
9 granted patents·16 pending applications·87 citations·filing 1985–2022
85Inventor score
Top patents by PatentIndex Score
25 records- 0193US6663863B2Method of inhibiting stenosis and restenosisMILLENNIUM PHARM INC·Filed 2001·Granted Dec 16, 2003·39 cites·5 claims
- 0287US8901281B2ILT3 binding molecules and uses thereforPONATH PAUL·Filed 2006·Granted Dec 2, 2014·13 cites·22 claims
- 0381US8815945B2Use of bis [thiohydrazide amide] compounds such as elesclomol for treating cancersNAGAI MASAZUMI·Filed 2011·Granted Aug 26, 2014·4 cites·16 claims
- 0479US4731244AMonoclonal antibody therapyORTHO PHARMA CORP·Filed 1985·Granted Mar 15, 1988·29 cites·16 claims
- 0571US7947272B2Compositions and methods of tolerizing a primate to an antigenTOLERX INC·Filed 2006·Granted May 24, 2011·1 cites·21 claims
- 0669US11230601B2Methods of using anti-lap antibodiesTILOS THERAPEUTICS INC·Filed 2018·Granted Jan 25, 2022·1 cites·14 claims
- 0768US2023312747A1Compositions and Methods for Treating CancerSEAGEN INC·Filed 2022·Application pending·0 cites
- 0858US2015139986A1Ilt3 binding molecules and uses thereforMERCK SHARP & DOHME·Filed 2014·Application pending·0 cites
- 0958US2005214299A1Method of inhibiting stenosis and restenosisMILLENNIUM PHARM INC·Filed 2003·Application pending·0 cites
- 1057US2022017612A1Anti-lap antibody variants and uses thereofTILOS THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1156US11130802B2Anti-lap antibody variantsTILOS THERAPEUTICS INC·Filed 2019·Granted Sep 28, 2021·0 cites·18 claims
- 1256US7541443B2Anti-CD4 antibodiesTOLERRX INC·Filed 2003·Granted Jun 2, 2009·0 cites·13 claims
- 1356US2009318357A1Molecules Preferentially Associated with Effector T Cells or Regulatory T Cells and Methods of Their UseTOLERX INC·Filed 2009·Application pending·0 cites
- 1455US2025032493A1Methods for Treating Diseases Using MALT1 InhibitorsRARIFIED BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 1552US2020247902A1Compositions and methods for treating cancerSEATTLE GENETICS INC·Filed 2017·Application pending·0 cites
- 1651US2008112949A1Optimized dosing with anti-CD4 antibodies for tolerance induction in primatesTOLERX INC·Filed 2007·Application pending·0 cites
- 1748US2005032725A1Molecules preferentially associated with effector T cells or regulatory T cells and methods of their useTOERRX INC·Filed 2003·Application pending·0 cites
- 1848US2004175381A1Inducing tolerance in primatesTOLERRX INC·Filed 2003·Application pending·0 cites
- 1946US2002147312A1Hybrid antibodies and uses thereofFiled 2002·Application pending·0 cites
- 2046US2006002921A1Optimized dosing with anti-CD4 antibodies for tolerance induction in primatesTOLERRX INC·Filed 2005·Application pending·0 cites
- 2144US11497733B2Combination therapy of HSP90 inhibitors and PD-1 inhibitors for treating cancerSYNTA PHARMACEUTICALS CORP·Filed 2016·Granted Nov 15, 2022·0 cites·13 claims
- 2244US2011008330A1Compositions and methods of tolerizing a primate to an antigenFREWIN MARK·Filed 2010·Application pending·0 cites
- 2343US2003108518A1TRX1 antibody and uses thereforFiled 2002·Application pending·0 cites
- 2441US2004166099A1Molecules preferentially associated with effector T cells and methods of their useTOLERRX INC·Filed 2003·Application pending·0 cites
- 2540US2005048587A1Methods for identifying tolerance modulatory compounds and uses thereforTOLERRX INC·Filed 2004·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →